Takeda Oct 19, 2021 Calithera Biosciences Acquires Takeda Cancer Drugs in $45M Deal Sep 16, 2021 FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC Jul 30, 2021 Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines Jul 1, 2021 FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor Apr 28, 2021 FDA Accepts Takeda's NDA for EGFR Exon20 Insertion-Mutated NSCLC Treatment Mar 24, 2021 Drugmakers Join Vineti to Promote Enhanced Standards for Personalized Cell Therapies Jan 28, 2021 Takeda Announces Updated Data From Mobocertinib Study in EGFR Exon20-Mutated NSCLC Jan 12, 2021 JP Morgan Healthcare, Day 1: Merck KGaA, Mirati, Agios, Tempus, Bristol Myers, Amgen, and More Dec 10, 2020 UK's NICE Recommends Takeda's Alunbrig for ALK Inhibitor-Naïve Advanced NSCLC Sep 18, 2020 Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies May 26, 2020 Takeda's Alunbrig Gets First-Line FDA Approval With Abbott CDx in ALK-Positive Lung Cancer May 1, 2020 Takeda's Mobocertinib Moves Into Larger NSCLC Studies After Promising Efficacy in EGFR Exon 20 Insertions Apr 6, 2020 European Commission Approves Takeda's Alunbrig for First-Line ALK-positive Lung Cancer Mar 31, 2020 Takeda's Adcetris Plus Chemotherapy Garners Positive CHMP Opinion in CD30-Positive sALCL Mar 2, 2020 CHMP Recommends European Approval of Takeda's Alunbrig for ALK-Positive NSCLC Feb 24, 2020 Takeda's Alunbrig sNDA for ALK-Positive Non-Small Cell Lung Cancer Accepted by FDA Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
